Fat – pharmacological therapies

Zheng H, Liu M, Li S, et al. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Front Endocrinol 2021;12:706914. https://doi.org/10.3389/fendo.2021.706914

Astrup A, Carraro R, Finer N, et al; NN8022-1807 Investigators. Safety, tol- erability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36(6):843-54. https://doi.org/10.1038/ijo.2011.158.

Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892.

Davies MJ, Bergenstal R, Bode B, et al; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA 2015;314(7):687-99. https://doi.org/10.1001/jama.2015.9676.

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in in- dividuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond) 2016; 40(8):1310-19. https://doi.org/10.1038/ijo.2016.52.

Wadden TA, Hollander P, Klein S, et al; NN8022-1923 Investigators. Weight maintenance and additional weight loss with liraglutide after low-calorie- diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37(11):1443-51. https://doi.org/10.1038/ijo.2013.120. Epub 2013 Jul 1. Erratum in: Int J Obes (Lond) 2013;37(11):1514. Erratum in: Int J Obes (Lond) 2015;39(1):187. PMID: 23812094.

Peter R, Bain SC. Safety of injectable semaglutide for type 2 diabetes. Expert Opin Drug Saf 2020;19(7):785-98. https://doi.org/10.1080/14740338.2020.1772230. Epub 2020 Jun 4. PMID: 32428416.

Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treat- ment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring) 2020;28(6):1050-1061. https://doi.org/10.1002/oby.22794.

Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once- Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384(11):989-1002. https:// doi.org/10.1056/NEJMoa2032183.

Davies M, Færch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- controlled, phase 3 trial. Lancet 2021;397(10278):971-84. https://doi.org/ 10.1016/S0140-6736(21)00213-0.

Wadden TA, Bailey TS, Billings LK, et al; STEP 3 Investigators. Effect of Sub- cutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021;325(14):1403-13. https://doi.org/ 10.1001/jama.2021.1831.

Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414-25. https://doi.org/ 10.1001/jama.2021.3224.

Rubino DM, Greenway FL, Khalid U, et al; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022;327(2):138-50. https://doi.org/ 10.1001/jama.2021.23619.

https://www.nice.org.uk/news/article/nice-recommends-new-drug-for-peo- ple-living-with-obesity

https://clinicaltrials.gov/ct2/show/NCT05035095

https://clinicaltrials.gov/ct2/show/NCT05394519

Nauck MA, Quast DR, Meier JJ. Another milestone in the evolution of GLP- 1-based diabetes therapies. Nat Med 2021;27(6):952-3. https://doi.org/ 10.1038/s41591-021-01394-7.

Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab 2018;18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009.

Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Ag- onist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther 2021;12(1):143-157. https://doi.org/10.1007/s13300-020- 00981-0.

Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022 Jul 21;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.

Park CS, Choi YJ, Rhee TM, et al. U-Shaped Associations Between Body Weight Changes and Major Cardiovascular Events in Type 2 Diabetes Mellitus: A Longitudinal Follow-up Study of a Nationwide Cohort of Over

5 Million. Diabetes Care 2022;45(5):1239-46. https://doi.org/10.2337/dc21-2299.

Goldberg RB, Orchard TJ, Crandall JP, et al; Diabetes Prevention Program Research Group. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation 2022;145(22):1632-41. https://doi.org/10.1161/CIRCULATIONAHA.121.056756.

Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovas- cular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J 2020;229:61-69. https://doi.org/10.1016/ j.ahj.2020.07.008.

Davies MJ, Aroda VR, Collins BS et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45(11):2753-86. https://doi.org/10.2337/dci22-0034.